Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (NASDAQ:ALNY) and Bausch Health Companies Inc (NYSE:BHC).
Alnylam Pharma (ALNY)
In a report released today, Madhu Kumar from B.Riley FBR reiterated a Buy rating on Alnylam Pharma, with a price target of $230. The company’s shares closed on Friday at $86.75, close to its 52-week low of $84.48.
Kumar commented:
“Friday, after market close, Pharmaceuticals (IONS) and Akcea Therapeutics (AKCA) announced the U.S. approval of transthyretin (TTR) antisense oligonucleotide (ASO) Tegsedi (the label can be found here). Despite the approval, we view this as a positive event for Alnylam Pharmaceuticals (ALNY) shares, as Tegsedi’s boxed warning and risk evaluation and mitigation strategy (REMS) reflect the TTR ASO’s materially inferior safety profile to Alnylam’s lead asset, TTR RNAi drug Onpattro, in our opinion. We remind investors of our conviction in Onpattro’s leadership in the hATTR therapeutic landscape, with ALNY’s TTR RNAi franchise representing $141.21 (61%) of our price target. After model updates, we thus reiterate our ALNY Buy rating and $230 price target.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 20.5% and a 48.3% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $146.77 average price target, a 69.2% upside from current levels. In a report issued on September 27, Chardan Capital also reiterated a Buy rating on the stock with a $180 price target.
.
See today’s analyst top recommended stocks >>
Bausch Health Companies Inc (BHC)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Bausch Health Companies Inc, with a price target of $25. The company’s shares closed on Friday at $26.32, close to its 52-week high of $28.45.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.9% and a 38.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Fennec Pharmaceuticals Inc.
Bausch Health Companies Inc has an analyst consensus of Moderate Buy, with a price target consensus of $26, which is a -1.2% downside from current levels. In a report released today, RBC Capital also maintained a Hold rating on the stock with a $30 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
